Encorafenib and Ivosidenib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Ivosidenib
Encorafenib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced encorafenib exposure, reduced efficacy of encorafenib and an increased risk of QT interval prolongation
Interaction Deep Dive
Avoid concomitant administration of encorafenib with a strong CYP3A4 inducer that prolongs the QTc interval as it may reduce encorafenib exposure, may also reduce efficacy of encorafenib, and additively prolong the QTc interval. If concomitant use cannot be avoided, monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during encorafenib administration. Withhold encorafenib until QTcF less than or equal to 500 ms, resume at reduced dose. If more than one recurrence, permanently discontinue encorafenib. Also, permanently discontinue encorafenib for QTcF more than 500 ms1.
Why it happens (mechanism)
Induction of CYP3A4-mediated encorafenib metabolism; additive QT interval prolongation
Common questions
Can I take Encorafenib and Ivosidenib together?
Reduced encorafenib exposure, reduced efficacy of encorafenib and an increased risk of QT interval prolongation Always confirm with your pharmacist or prescriber before making any change.
How serious is the Encorafenib and Ivosidenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Encorafenib or Ivosidenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: BRAFTOVI(R) oral capsules, encorafenib oral capsules. Array BioPharma Inc (per FDA), Boulder, CO, 2024. DailyMed
Keep reading about Ivosidenib
Keep reading about Encorafenib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist